Recent increase of breast cancer incidence among women under the age of forty

Geneva Cancer Registry, Institute for Social and Preventive Medicine, University of Geneva, 55, bd de la Cluse, 1205 Geneva, Switzerland.
British Journal of Cancer (Impact Factor: 4.84). 07/2007; 96(11):1743-6. DOI: 10.1038/sj.bjc.6603783
Source: PubMed


Using data from the Geneva Cancer Registry, we found that in 2002-2004, breast cancer incidence in women aged 25-39 years increased by 46.7% per year (95% CI: 7.1-74.0, P=0.015), which surveillance or detection bias may not fully explain.

Download full-text


Available from: Isabelle Neyroud-Caspar,
    • "In Geneva, Switzerland, breast cancer incidence in women <40 years old doubled between 1995 and 2004. Of note, the mean annual increase was much higher in the last three years of the study [4]. Similar trend was also observed Spain [5] and Netherland [6]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Breast cancer in young women has different clinical and pathologic features and a more aggressive biological behavior when compared to breast cancers in older women. However, information is limited to the group of very young women (≤25 years). The aim of the present study was to investigate the pathological characteristics of breast cancer in 149 Brazilian women who were ≤25 years old at the time of breast cancer diagnosis. Tumor samples diagnosed between 2003 and 2009 were analyzed from the archives of the Bacchi Laboratory. In our series of 149 Brazilian women ≤25 years, 8.7% presented with in situ disease only. Of 136 invasive carcinomas, 91.9% were of the ductal type and 45.6% were of histological grade III. Overall, estrogen receptor (ER) was positive in 59.6% cases, and HER2 overexpression was detected in 32.8%. We also found a low prevalence of Luminal A cases and a high prevalence of Triple Negative cases. Statistical analysis showed that HER2 and basal-like groups had a lower overall survival expectation. Follow-up data showed high frequencies of regional lymph node metastasis, distant metastasis, and tumor-related deaths. The present study represents the largest series of breast cancer arising in women ≤25 years and establishes the main clinical, pathological, immunohistochemical and follow-up features of this population. Copyright © 2015 Elsevier Ltd. All rights reserved.
    Breast (Edinburgh, Scotland) 05/2015; 24(4). DOI:10.1016/j.breast.2015.04.002 · 2.38 Impact Factor
  • Source
    • "The majority of breast cancers are estrogen-dependent disease with increasing morbidity and mortality rates in most western societies over the last few decades [1-3]. The most common therapeutic strategies for breast cancer, including excision surgery (mastectomy), radiotherapy, chemotherapy, monoclonal antibodies and endocrine therapies, impact on women’s quality of life [4]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Background Ginkgo biloba extract (GbE) is used extensively by breast cancer patients undergoing treatment with Tamoxifen (TAM). Thus, the present study investigated the effects of GbE in female Sprague–Dawley (SD) rats bearing chemically-induced mammary tumors and receiving TAM. Methods Animals bearing mammary tumors (≥1 cm in diameter) were divided into four groups: TAM [10 mg/kg, intragastrically (i.g.)], TAM plus GbE [50 and 100 mg/kg, intraperitoneally (i.p.)] or an untreated control group. After 4 weeks, the therapeutic efficacy of the different treatments was evaluated by measuring the tumor volume (cm3) and the proportions of each tumor that were alive, necrotic or degenerative (mm2). In addition, labeling indexes (LI%) were calculated for cell proliferation (PCNA LI%) and apoptosis (cleaved caspase-3 LI%), expression of estrogen receptor-alpha (ER-α) and p63 biomarkers. Results Overall, the tumor volume and the PCNA LI% within live tumor areas were reduced by 83% and 99%, respectively, in all TAM-treated groups when compared to the untreated control group. GbE treatment (100 mg/kg) reduced the proportions of live (24.8%) and necrotic areas (2.9%) (p = 0.046 and p = 0.038, respectively) and significantly increased the proportion of degenerative areas (72.9%) (p = 0.004) in mammary tumors when compared to the group treated only with TAM. The expression of ER-α, p63 and cleaved caspase-3 in live tumor tissues was not modified by GbE treatment. Conclusions Co-treatment with 100 mg/kg GbE presented a slightly beneficial effect on the therapeutic efficacy of TAM in female SD rats bearing mammary tumors.
    BMC Complementary and Alternative Medicine 05/2013; 13(1):93. DOI:10.1186/1472-6882-13-93 · 2.02 Impact Factor
  • Source
    • "Approximately 3–7% of women with early-stage breast cancer are under 40 years of age at diagnosis (Australian Institute of Health and Welfare (AIHW) and Australasian Association of Cancer Registries (AACR), 2004; Bouchardy et al, 2007; Peate et al, 2009; American Cancer Society, 2011–2012). Most women receive adjuvant chemotherapy, which is often associated with diminished ovarian function (Bines et al, 1996; Goodwin et al, 1999; Minton and Munster, 2002). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Fertility is a priority for many young women with breast cancer. Women need to be informed about interventions to retain fertility before chemotherapy so as to make good quality decisions. This study aimed to prospectively evaluate the efficacy of a fertility-related decision aid (DA). A total of 120 newly diagnosed early-stage breast cancer patients from 19 Australian oncology clinics, aged 18-40 years and desired future fertility, were assessed on decisional conflict, knowledge, decision regret, and satisfaction about fertility-related treatment decisions. These were measured at baseline, 1 and 12 months, and were examined using linear mixed effects models. Compared with usual care, women who received the DA had reduced decisional conflict (β=-1.51; 95%CI: -2.54 to 0.48; P=0.004) and improved knowledge (β=0.09; 95%CI: 0.01-0.16; P=0.02), after adjusting for education, desire for children and baseline uncertainty. The DA was associated with reduced decisional regret at 1 year (β=-3.73; 95%CI: -7.12 to -0.35; P=0.031), after adjusting for education. Women who received the DA were more satisfied with the information received on the impact of cancer treatment on fertility (P<0.001), fertility options (P=0.005), and rated it more helpful (P=0.002), than those who received standard care. These findings support widespread use of this DA shortly after diagnosis (before chemotherapy) among younger breast cancer patients who have not completed their families.
    British Journal of Cancer 03/2012; 106(6):1053-61. DOI:10.1038/bjc.2012.61 · 4.84 Impact Factor
Show more